bullish
Scivita Medical Technology (SMT HK) Pre-IPO: A Promising Game Changer with First-Mover Advantage
418 Views18 Dec 2021 22:40
SUMMARY
- Scivita Medical Technology (SMT HK) mainly focuses on single-use medical endoscopes, which comprises of three approved products and 11 pipeline products.
- Global single-use medical endoscope market is a limited competition market, with high growth potential. The risk of contamination will continue to be the key driver of single-use endoscopes.
- Scivita is at its early stage of commercialization in China and overseas market. Technical features of Scivita single-use endoscopes are comparable or superior to industry leader Ambu.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Scivita Medical Technology (SMT HK) Pre-IPO: A Promising Game Changer with First-Mover Advantage18 Dec 2021
x